2024
Assessing interest in addressing religion and spirituality in a recovery program for adults with serious mental illness
Matsuura T, Klee A, Heikkila H, Cooke J, Edens E, Rosenheck R. Assessing interest in addressing religion and spirituality in a recovery program for adults with serious mental illness. Journal Of Public Mental Health 2024, ahead-of-print DOI: 10.1108/jpmh-06-2024-0073.Peer-Reviewed Original ResearchMental Health and Social Correlates of Reincarceration of Youths as Adults.
Buchanan A, Zhou B, Rhee T, Stefanovics E, Rosenheck R. Mental Health and Social Correlates of Reincarceration of Youths as Adults. The Journal Of The American Academy Of Psychiatry And The Law 2024, 52: 294-303. PMID: 39048309, DOI: 10.29158/jaapl.240039-24.Peer-Reviewed Original ResearchSubstance use disordersU.S. prison populationIncarceration of childrenAssociated with incarcerationCriminological researchPrison populationReduce reincarcerationHeightened scrutinyReincarcerationNational Epidemiologic SurveyIncarcerationCross-sectional representative surveyPsychiatric treatmentU.S. populationBipolar disorderClinical interviewNESARC-IIIPsychometric instrumentsRepresentative surveySocial correlatesMental healthRelated conditionsDisordersU.S.AdultsPotential Role for Buprenorphine in the Management of Comorbid Depression Among People with Chronic Pain and Long-Term Opioid Therapy Dependence
Manhapra A, Rosenheck R, Becker W. Potential Role for Buprenorphine in the Management of Comorbid Depression Among People with Chronic Pain and Long-Term Opioid Therapy Dependence. 2024, 148-164. DOI: 10.1093/9780197675250.003.0009.Peer-Reviewed Original ResearchLong-term opioid therapyKappa-opioid receptorsChronic painOpioid receptorsKappa-opioid receptor antagonismManagement of comorbid depressionTherapeutic agentsMOR agonismOpioid therapyOpioid taperAntidepressant effectsWorsening painOpioid dependenceSafety profileAgonist actionPoor outcomeClinical trialsAssociated with worsening depressionPainEtiological driversBuprenorphineReceptor affinityComorbid depressionOpioidReceptorsCommunity perspectives to inform the development of a radio program to destigmatize mental illness in rural Uganda: a qualitative study
Lee Y, Fickling B, Goode M, Gallaher A, Kazungu R, Coffin P, Abdel-Megid M, Isabirye F, Ssekalo I, Ashaba S, Rosenheck R, Tsai A. Community perspectives to inform the development of a radio program to destigmatize mental illness in rural Uganda: a qualitative study. Journal Of Global Health Reports 2024, 8 DOI: 10.29392/001c.120280.Peer-Reviewed Original ResearchMental illness stigmaCommunity health workersMental illnessIllness stigmaHealth workersRural UgandaDecrease mental illness stigmaReduce mental illness stigmaHealthcare seeking behaviorDestigmatize mental illnessOne-on-oneFocus group discussionsProgram acceptabilityScalable interventionsFramework methodResults ParticipantsBusoga regionProgram interventionsSub-themesFocus groupsQualitative studySeeking behaviorSeeking treatmentIndividual recoveryCommunity supportDifferences in Mental Illness Stigma by Disorder and Gender: Population-Based Vignette Randomized Experiment in Rural Uganda.
Lee Y, Christ R, Mbabazi R, Dabagia J, Prendergast A, Wykoff J, Dasari S, Safai D, Nakaweesi S, Aturinde S, Galvin M, Akena D, Ashaba S, Waiswa P, Rosenheck R, Tsai A. Differences in Mental Illness Stigma by Disorder and Gender: Population-Based Vignette Randomized Experiment in Rural Uganda. PLOS Mental Health 2024, 1: e0000069. PMID: 39188639, PMCID: PMC11345708, DOI: 10.1371/journal.pmen.0000069.Peer-Reviewed Original ResearchMental illness stigmaIllness stigmaAnxiety disordersMental disordersLevels of mental illness stigmaRural UgandaImprove population mental healthAnti-stigma initiativesLevel of stigmaPopulation mental healthGeneralized anxiety disorderDSM-5 criteriaAlcohol use disorderEmpirical p-valuesVignette studyMental illnessPairwise mean comparisonsDistricts of UgandaPopulation-basedMental healthDepressive disorderGender combinationsUse disorderSecondary analysisStudy participantsNational trends and correlates of treatment resistance in major depressive episode and associated suicidal ideation and behaviors among adults in the United States
Rhee T, Bommersbach T, Rosenheck R, Nierenberg A, McIntyre R. National trends and correlates of treatment resistance in major depressive episode and associated suicidal ideation and behaviors among adults in the United States. Journal Of Affective Disorders 2024, 358: 342-349. PMID: 38734245, DOI: 10.1016/j.jad.2024.05.044.Peer-Reviewed Original ResearchTreatment-resistant depressionMajor depressive episodeSuicidal ideationDepressive episodeAverage annual percent changePast-year suicide attemptPast-year suicidal ideationPast-year major depressive episodePrevalence of suicidal ideationSuicide prevention effortsNational Survey of Drug Use and HealthUS adultsSuicide attemptsDrug Use and HealthNon-pharmacological interventionsHigh-risk populationIdeationAnnual percent changeTreatment resistanceNo significant differenceDiagnostic criteriaPreventive servicesAdultsPercent changeSignificant differenceAssociation of mental health related quality of life and other factors with treatment seeking for substance use disorders: A comparison of SUDs rooted in legal, partially legal, and illegal substances
Havlik J, Rhee T, Rosenheck R. Association of mental health related quality of life and other factors with treatment seeking for substance use disorders: A comparison of SUDs rooted in legal, partially legal, and illegal substances. PLOS ONE 2024, 19: e0302544. PMID: 38683850, PMCID: PMC11057773, DOI: 10.1371/journal.pone.0302544.Peer-Reviewed Original ResearchConceptsIllicit substance use disordersCannabis use disorderSubstance use disordersMental health-related quality of lifeUse disorderTreatment usePast-year CUDRates of treatment usePast-year substance use disorderMental health-related qualityMental health related qualityBehavioral health factorsLegal statusNegative associationNESARC-IIISUD treatment useMultiple regression analysisDisordersHealth-related quality of lifeIllegal substancesHealth related qualityUnadjusted analysisQuality of lifeAUDDiagnostic factorsAssociative Stigma Among Community Mental Health Professionals in Work and Nonwork Settings
Jegede O, Matsuura T, Rosenheck R. Associative Stigma Among Community Mental Health Professionals in Work and Nonwork Settings. Stigma And Health 2024 DOI: 10.1037/sah0000529.Peer-Reviewed Original ResearchAssociated stigmaCommunity mental health professionalsCommunity mental health centerUrban community mental health centerMental health stigmaNational sampleTotal scoreMental health centerMental health cliniciansMental health professionalsNonwork settingsHealth stigmaStigma ScaleAdequate internal consistencyAS total scoreHealth professionalsHealth cliniciansWork settingsHealth centersMental illnessInternal consistencyStigmaCliniciansSocial ostracismScores
2023
Are opioids effective analgesics and is physiological opioid dependence benign? Revising current assumptions to effectively manage long‐term opioid therapy and its deprescribing
Manhapra A, MacLean R, Rosenheck R, Becker W. Are opioids effective analgesics and is physiological opioid dependence benign? Revising current assumptions to effectively manage long‐term opioid therapy and its deprescribing. British Journal Of Clinical Pharmacology 2023, 90: 2962-2976. PMID: 37990580, PMCID: PMC11563311, DOI: 10.1111/bcp.15972.Peer-Reviewed Original ResearchLong-term opioid therapyOpioid therapyFunctional gainsChronic pain syndromeMaximum functional recoveryOngoing opioid crisisParadoxical worseningAnalgesic benefitAnalgesic therapyPain reliefPain syndromeEffective analgesicMost patientsAntinociceptive effectAntinociceptive systemChronic painFunctional recoveryOpioid actionOpioid dependenceMedical instabilityFunctional improvementPlacebo effectClinical principlesOpioid crisisTherapeutic inductionEfficacy and safety of ketamine-assisted electroconvulsive therapy in major depressive episode: a systematic review and network meta-analysis
Rhee T, Shim S, Popp J, Trikalinos T, Rosenheck R, Kellner C, Seiner S, Espinoza R, Forester B, McIntyre R. Efficacy and safety of ketamine-assisted electroconvulsive therapy in major depressive episode: a systematic review and network meta-analysis. Molecular Psychiatry 2023, 29: 750-759. PMID: 38123725, DOI: 10.1038/s41380-023-02366-8.Peer-Reviewed Original ResearchMajor depressive episodeStandardized mean differenceElectroconvulsive therapyAnesthetic agentsDepressive symptomsDepressive episodeRelative riskDiagnosis of MDESystematic reviewKetamine-treated patientsSafety of ketamineSerious adverse eventsResultsTwenty-two studiesMethodsPubMed/MEDLINEImportant clinical considerationsRandom-effects modelCognitive performanceAdverse eventsAntidepressant efficacyECT useTrials RegistryClinical efficacyCochrane LibraryWorse outcomesPatient profilesTwelve-month outcomes of a destigmatizing theatrical intervention in rural Uganda
Lee Y, Christ R, Blackwell S, Rauben K, Krause A, Monnig E, Ssekalo I, Iheanacho T, Rosenheck R. Twelve-month outcomes of a destigmatizing theatrical intervention in rural Uganda. Current Psychology 2023, 43: 14676-14685. DOI: 10.1007/s12144-023-05427-x.Peer-Reviewed Original ResearchMental illness stigmaIllness stigmaTwelve-month outcomesLow-income settingsLong-term effectivenessMental health stigmaPrimary outcomeStudy participantsHealth stigmaRural UgandaConfidence intervalsInterventionEffect sizeMonthsOutcomesAverage improvementStigmaAcceptance ScaleParticipantsFollowBaselineWeeksReceipt of Electroconvulsive Therapy in Outpatient Settings in a National Sample of Privately Insured Patients With Mood Disorders
Agbese E, Leslie D, Rosenheck R. Receipt of Electroconvulsive Therapy in Outpatient Settings in a National Sample of Privately Insured Patients With Mood Disorders. Journal Of Ect 2023, 40: 31-36. PMID: 37530796, DOI: 10.1097/yct.0000000000000950.Peer-Reviewed Original ResearchConceptsElectroconvulsive therapyReduce cost barriersMood disordersHealth care costsOutpatient settingPrivately insured patientsCare costsNational sample of privately insured patientsProportion of privately insured patientsReceipt of electroconvulsive therapyInpatient electroconvulsive therapyCost barriersOutpatient electroconvulsive therapyMarketScan Commercial DatabaseDepressive disorderCompared 4 groupsGroup differencesInpatient settingMoodNational sampleEffective treatmentPatientsDisordersOutpatientsHealthExamining the relationship of concurrent obesity and tobacco use disorder on the development of substance use disorders and psychiatric conditions: Findings from the NESARC-III
Fields L, Roberts W, Schwing I, McCoy M, Verplaetse T, Peltier M, Carretta R, Zakiniaeiz Y, Rosenheck R, McKee S. Examining the relationship of concurrent obesity and tobacco use disorder on the development of substance use disorders and psychiatric conditions: Findings from the NESARC-III. Drug And Alcohol Dependence Reports 2023, 7: 100162. PMID: 37159814, PMCID: PMC10163607, DOI: 10.1016/j.dadr.2023.100162.Peer-Reviewed Original ResearchTobacco use disorderSubstance use disordersBody mass indexUse disordersPsychiatric conditionsRisk of SUDAdditional substance use disordersSingle health conditionsRelated Conditions Wave IIIWorse health outcomesNational Epidemiological SurveyPsychiatric disorder diagnosisHarmful substance useDSM-5 criteriaConcurrent obesityComorbid obesityMass indexSUD diagnosisRisk factorsObesityComorbid diagnosesEpidemiological surveyHealth outcomesNESARC-IIIDisorder diagnosisVictimization in schizophrenia and its relation to violence
Buchanan A, Stefanovics E, Rosenheck R. Victimization in schizophrenia and its relation to violence. Schizophrenia Research 2023, 255: 52-58. PMID: 36963231, DOI: 10.1016/j.schres.2023.03.018.Peer-Reviewed Original ResearchConceptsIntervention Effectiveness (CATIE) trialMental health symptomsStudy entryCross-sectional designAntipsychotic treatmentEffectiveness trialSchizophrenia symptomsMultivariate analysisHealth symptomsSchizophreniaViolent behaviorSubstance useSymptomsRecent victimizationPotential causesAggressive behaviorChildhood experiencesBaselineMore incidentsCorrelatesTreatmentVictims of violenceSexual abuseClose friendsMost perpetratorsIncreasing Use of Cannabis for Medical Purposes Among U.S. Residents, 2013–2020
Rhee T, Rosenheck R. Increasing Use of Cannabis for Medical Purposes Among U.S. Residents, 2013–2020. American Journal Of Preventive Medicine 2023, 65: 528-533. PMID: 36918131, PMCID: PMC10440227, DOI: 10.1016/j.amepre.2023.03.005.Peer-Reviewed Original ResearchConceptsMedical cannabis useAverage annual percentage changeAnnual percentage changeUse of cannabisCannabis useClinical subgroupsPercentage changeMultivariable-adjusted modelsCorrelates of cannabisSimilar significant increaseMedical cannabisDrug useDistrict of ColumbiaCannabisMedical purposesNationwide increaseSignificant increaseNational surveyDichotomous questionsU.S. residentsSubgroupsTemporal trendsAssociation of Recent and Past Suicide Attempts With Health-Related Quality of Life.
Bommersbach T, Rosenheck R, Rhee T. Association of Recent and Past Suicide Attempts With Health-Related Quality of Life. The Journal Of Clinical Psychiatry 2023, 84 PMID: 36856537, DOI: 10.4088/jcp.22m14441.Peer-Reviewed Original ResearchConceptsMental component scorePhysical component scoreSuicide prevention initiativesSuicide attemptsOverall health-related qualityMajor public health priorityPrevention initiativesHealth-related qualitySubstance use comorbiditiesMeasures of HRQOLRelated Conditions Wave IIILower MCS scoresMultivariable regression analysisPublic health prioritySubstance use disordersComponent scoresNational Epidemiologic SurveyQuality of lifeRecent suicide attemptAssociation of suicidePast suicide attemptsPrior attemptsMCS scoresUnadjusted analysesHealth priorityMultimorbidity and Correlates of Comorbid Depression and Generalized Anxiety Disorder in a Nationally Representative US Sample
Jegede O, Stefanovics E, Rhee T, Rosenheck R. Multimorbidity and Correlates of Comorbid Depression and Generalized Anxiety Disorder in a Nationally Representative US Sample. The Journal Of Nervous And Mental Disease 2023, 211: 355-361. PMID: 36807207, DOI: 10.1097/nmd.0000000000001625.Peer-Reviewed Original ResearchConceptsMajor depressive disorderAdditional psychiatric diagnosesRepresentative US sampleComorbid groupPsychiatric disordersPsychiatric diagnosisPoor mental health qualityMental health-related qualityPoorer mental health-related qualityAnxiety disordersHealth-related qualityAdditional psychiatric disordersNationally Representative US SampleMental health qualityLogistic regression analysisSubstance use disordersNational Epidemiologic SurveyMDD-only groupRelated Conditions-IIISingle disorder groupsGeneralized anxiety disorderSingle diagnosis groupsPsychiatric comorbidityComorbid depressionDepressive disorderMental health problems of black and white children in a nationally representative epidemiologic survey
Bommersbach T, Rhee T, Jegede O, Rosenheck R. Mental health problems of black and white children in a nationally representative epidemiologic survey. Psychiatry Research 2023, 321: 115106. PMID: 36791593, DOI: 10.1016/j.psychres.2023.115106.Peer-Reviewed Original ResearchConceptsMental health problemsHealth problemsWhite childrenAdverse mental health problemsBlack childrenMental health servicesNon-Hispanic blacksDepression/anxietyMental health conditionsInternalizing conditionsPotential confoundersRoutine screeningChild healthConduct problemsEpidemiologic SurveyHealth servicesMultivariate analysisSocio-economic disadvantageHealth conditionsRacial differencesChildrenNational surveySuicide ratesChildhood experiencesGreater exposureCan multisite clinical trial results change clinical practice? Use of long-acting injectable risperidone nationally in the Veterans Health Administration
Rosenheck R, Anand S, Kurtz S, Hau C, Smedberg D, Pontzer J, Ferguson R, Davis C. Can multisite clinical trial results change clinical practice? Use of long-acting injectable risperidone nationally in the Veterans Health Administration. Trials 2023, 24: 85. PMID: 36747254, PMCID: PMC9900548, DOI: 10.1186/s13063-023-07094-6.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychoticsLAI risperidoneClinical practiceLAI second-generation antipsychoticsInjectable second-generation antipsychoticsPractical clinical trialsVeterans Health AdministrationClinical trial resultsStudy publicationDiagnosis of schizophreniaNational administrative dataLongitudinal observational analysisLAI paliperidoneOral antipsychoticsReal-world practiceInjectable risperidoneTrial findingsClinical trialsLAI treatmentRisperidoneSchizoaffective disorderHealth AdministrationCooperative StudyAntipsychoticsDrug expendituresImpact of multi-site clinical trial results on clinical practice: Use of risperidone to treat PTSD nationally in the veterans health administration
Rosenheck R, Kurtz S, Anand S, Hau C, Smedberg D, Sicilia R, Pontzer J, Ferguson R. Impact of multi-site clinical trial results on clinical practice: Use of risperidone to treat PTSD nationally in the veterans health administration. Psychiatry Research 2023, 321: 115071. PMID: 36720177, DOI: 10.1016/j.psychres.2023.115071.Peer-Reviewed Original ResearchConceptsClinical practiceNational VHA administrative dataOral second-generation antipsychoticsUse of risperidoneVHA administrative dataSecond-generation antipsychoticsMulti-site clinical trialVeterans Health AdministrationClinical trialsEffectiveness trialHealth AdministrationRisperidoneCooperative StudyYear of publicationAdministrative dataPTSDTrialsYearsAntipsychoticsStudy resultsAdministration